Table 2.
Primary analysis: Confounder-adjusted outcome occurrence rate ratios for the association between warfarin and serious hypoglycemia when used concomitantly with a sulfonylurea or metformin
| Object drug (N=number of outcomesa) |
Risk Window (days)b | Rate ratioc (95% CI) |
|---|---|---|
| glimepiride (N=654) |
Overall | 1.47 (1.07, 2.02) |
| 0-30 | 1.59 (1.13, 2.23) | |
| 31-60 | 1.28 (0.85, 1.94) | |
| 61-120 | 1.22 (0.76, 1.97) | |
| >120 | 1.56 (0.97, 2.50) | |
| glipizide (N=1,554) |
Overall | 1.20 (0.98, 1.46) |
| 0-30 | 1.19 (0.95, 1.49) | |
| 31-60 | 0.92 (0.69, 1.23) | |
| 61-120 | 1.04 (0.77, 1.42) | |
| >120 | 1.72 (1.29, 2.29) | |
| glyburide (N=1,405) |
Overall | 1.09 (0.88, 1.35) |
| 0-30 | 1.09 (0.86, 1.39) | |
| 31-60 | 0.87 (0.65, 1.18) | |
| 61-120 | 1.04 (0.76, 1.44) | |
| >120 | 1.57 (1.15, 2.15) | |
| metformin (N=1,197) |
Overall | 1.73 (1.38, 2.16) |
| 0-30 | 1.53 (1.17, 2.00) | |
| 31-60 | 1.37 (0.99, 1.89) | |
| 61-120 | 2.06 (1.53, 2.77) | |
| >120 | 2.26 (1.67, 3.05) |
CI: confidence interval.
a
Number of outcomes: number of serious hypoglycemia occurrence during the observation time for each object-precipitant drug pair.
b
Risk window (days): days within the exposed time (i.e., concomitant-use period) in the observation time since the initiation of the concomitant-use time.
c
Rate ratio: [(outcome occurrence rate of exposed time) / (outcome occurrence rate of unexposed time)], for each object-precipitant drug pair.